Andrew Dahl Sells 568 Shares of Edwards Lifesciences (NYSE:EW) Stock

Key Points

• Insider sale: Edwards Lifesciences SVP Andrew Dahl sold 568 shares at an average price of $86.08, totaling about $48,893. After the sale, he still owned 15,334 shares.
• Strong quarterly results: The company reported Q1 EPS of $0.78, topping estimates of $0.73, while revenue rose 16.7% year over year to $1.65 billion and also beat expectations.
• Wall Street remains positive: Analysts currently rate Edwards Lifesciences a Moderate Buy on average, with a consensus target price of $95.65. Several firms recently raised price targets, including BTIG Research and Piper Sandler.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) SVP Andrew Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares of the company's stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Edwards Lifesciences Price Performance

Shares of NYSE EW traded up $0.45 during midday trading on Friday, reaching $86.41. 7,265,912 shares of the company traded hands, compared to its average volume of 4,843,172. The firm has a market cap of $49.76 billion, a PE ratio of 45.96, a PEG ratio of 2.17 and a beta of 0.87. The stock's 50-day simple moving average is $81.66 and its 200-day simple moving average is $82.98. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $88.28. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analysts' expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business's revenue was up 16.7% on a year-over-year basis. During the same period last year, the business earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently modified their holdings of the stock. Level Four Advisory Services LLC boosted its holdings in Edwards Lifesciences by 3.7% during the third quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company's stock worth $257,000 after buying an additional 119 shares in the last quarter. Colonial Trust Co SC raised its position in shares of Edwards Lifesciences by 0.4% in the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company's stock valued at $2,504,000 after buying an additional 120 shares during the last quarter. Evermay Wealth Management LLC raised its position in shares of Edwards Lifesciences by 4.0% in the fourth quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company's stock valued at $282,000 after buying an additional 128 shares during the last quarter. Rehmann Capital Advisory Group increased its position in Edwards Lifesciences by 2.1% during the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock worth $546,000 after purchasing an additional 130 shares during the last quarter. Finally, Howard Capital Management Inc. increased its position in Edwards Lifesciences by 3.3% during the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company's stock worth $322,000 after purchasing an additional 132 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently weighed in on EW shares. BTIG Research raised their target price on Edwards Lifesciences from $98.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, April 24th. Robert W. Baird raised their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a "neutral" rating in a research note on Friday, April 24th. Wolfe Research upgraded Edwards Lifesciences from a "peer perform" rating to an "outperform" rating and set a $92.00 target price for the company in a research note on Wednesday, April 1st. Evercore restated an "outperform" rating and issued a $93.00 target price on shares of Edwards Lifesciences in a research note on Friday, April 24th. Finally, Piper Sandler restated an "overweight" rating and issued a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $95.65.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.